Patel Yesha S, Mehra Sarika
Department of Chemical Engineering, Indian Institute of Technology Bombay, Mumbai, India.
Front Microbiol. 2017 Oct 31;8:2075. doi: 10.3389/fmicb.2017.02075. eCollection 2017.
Prolonged chemotherapy as well as rapid development of antimicrobial resistance are two of the major concerns for treatment of mycobacterial infections. To enhance the effectiveness of current drug regimens, search for compounds having synergistic interaction with anti-mycobacterial drugs has become indispensable. Here, we have investigated the intervention by oxidative stress, a major factor in mycobacterial pathogenesis, in combination with rifampicin (RIF), a first-line drug used against . We have observed that a sub-inhibitory concentration of cumene hydroperoxide (CHP), a hydrophobic oxidant, synergistically reduced the minimum inhibitory concentration of RIF by fourfold, with a Fractional Inhibitory Concentration Index (FICI) of 0.45. Also, this interaction was found to be robust and synergistic against different strains of as well as on BCG, with FICI ranging from 0.3 to 0.6. Various physiological, biochemical and molecular parameters were explored to understand the mechanism of synergy. It was observed that increased membrane permeability owing to the presence of the oxidant, led to higher uptake of the drug. Moreover, downregulation of the hydroperoxide reductases by RIF, a transcriptional inhibitor, prevented quenching of the reactive oxygen species produced in the presence of CHP. The lipid soluble reactive species triggered autocatalytic lipid peroxidation (LPO), observed here as extensive membrane damage eventually leading to growth inhibition. Furthermore, it was seen that in combination with hydrogen peroxide (HO), the effect was only additive, establishing LPO as a key aspect leading toward synergism. To conclude, this work suggests that targeting the bacterial membrane by a radical species can have a significant impact on the treatment of tuberculosis.
长期化疗以及抗菌药物耐药性的快速发展是治疗分枝杆菌感染的两个主要问题。为提高当前药物治疗方案的有效性,寻找与抗分枝杆菌药物具有协同相互作用的化合物变得不可或缺。在此,我们研究了氧化应激(分枝杆菌发病机制中的一个主要因素)与利福平(RIF,一种用于治疗的一线药物)联合使用时的干预作用。我们观察到,亚抑制浓度的疏水性氧化剂氢过氧化异丙苯(CHP)可使RIF的最低抑菌浓度协同降低四倍,分数抑菌浓度指数(FICI)为0.45。此外,发现这种相互作用对不同菌株以及卡介苗(BCG)均具有强大的协同作用,FICI范围为0.3至0.6。我们探索了各种生理、生化和分子参数以了解协同作用的机制。观察到由于氧化剂的存在导致膜通透性增加,从而使药物摄取量更高。此外,转录抑制剂RIF对氢过氧化物还原酶的下调作用可防止在CHP存在下产生的活性氧被淬灭。脂溶性活性物质引发了自催化脂质过氧化(LPO),在此表现为广泛的膜损伤,最终导致生长抑制。此外,还发现与过氧化氢(HO)联合使用时,效果仅为相加作用,这表明LPO是导致协同作用的关键因素。总之,这项工作表明,通过自由基靶向细菌膜对结核病治疗可能具有重大影响。